Nguyen Y K
Department of Clinical Pharmacology and Research, Morton Plant Hospital, Clearwater.
J Fla Med Assoc. 1994 Jul;81(7):467-9.
Recombinant human granulocyte colony-stimulating factor (rhGCSF) has been commercially available for two years; yet unanswered questions need to be substantiated by clinical trials. The most extensively studied clinical application has been in chemotherapy-induced neutropenia. GCSF accelerates neutrophil recovery after bone marrow transplant, mobilizes bone marrow progenitor cells into peripheral blood harvesting then transplanted as supportive measures in patients undergoing intensive chemotherapy, and accelerates neutrophil recovery in patients with acute leukemias. GCSF is generally well-tolerated with only mild to moderate bone pain. Mild reversible elevation in lactate dehydrogenase, alkaline phosphatase, and uric acid has been reported. As data are obtained from ongoing trials, GCSF's clinical role will be expanded and better defined.
重组人粒细胞集落刺激因子（rhGCSF）已上市两年；然而，一些尚未解答的问题仍需通过临床试验来证实。研究最为广泛的临床应用是在化疗引起的中性粒细胞减少症方面。GCSF可加速骨髓移植后中性粒细胞的恢复，将骨髓祖细胞动员到外周血中进行采集，然后作为强化化疗患者的支持措施进行移植，并加速急性白血病患者中性粒细胞的恢复。GCSF一般耐受性良好，仅伴有轻度至中度骨痛。有报道称乳酸脱氢酶、碱性磷酸酶和尿酸有轻度可逆性升高。随着从正在进行的试验中获取数据，GCSF的临床作用将得到扩展并得到更好的界定。
